Shots:

• The P-III IMpassion131 study involves assessing of Tecentriq + paclitaxel vs PBO + paclitaxel- in 651 people in a ratio (2:1) with previously untreated- inoperable- LA/ m-TNBC
• The study did not meet its 1EPs of PFS for 1L treatment of people with m-TNBC) in the PD-L1+ population.  The data for 2EPs of OS showed a negative trend- however- the study was not powered for the 2EPs of OS and data were immature at the time of analysis while OS follow-up is planned to continue until the final analysis
• In the previous IMpassion130 study- Tecentriq + Abraxane demonstrated PFS benefit and- while not formally tested- showed improvements in OS for people with metastatic TNBC whose tumors express PD-L1

­ Ref: Roche | Image: Roche